159 related articles for article (PubMed ID: 15962764)
1. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor.
Harashima K; Akimoto T; Nonaka T; Tsuzuki K; Mitsuhashi N; Nakano T
Int J Radiat Biol; 2005 Jan; 81(1):63-76. PubMed ID: 15962764
[TBL] [Abstract][Full Text] [Related]
2. Radicicol potentiates heat-induced cell killing in a human oesophageal cancer cell line: the Hsp90 chaperone complex as a new molecular target for enhancement of thermosensitivity.
Akimoto T; Nonaka T; Harashima K; Sakurai H; Ishikawa H; Mitsuhashi N
Int J Radiat Biol; 2004 Jul; 80(7):483-92. PubMed ID: 15360086
[TBL] [Abstract][Full Text] [Related]
3. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
5. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
Chen L; Meng S; Wang H; Bali P; Bai W; Li B; Atadja P; Bhalla KN; Wu J
Mol Cancer Ther; 2005 Sep; 4(9):1311-9. PubMed ID: 16170022
[TBL] [Abstract][Full Text] [Related]
6. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.
Suzuki Y; Kondo Y; Hara S; Kimata R; Nishimura T
Int J Urol; 2010 Mar; 17(3):281-5. PubMed ID: 20409220
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.
Alexander B; Fishman AI; Green D; Choudhury MS; Konno S
Urol Oncol; 2013 Jan; 31(1):104-9. PubMed ID: 21795077
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 as a therapeutic target in prostate cancer.
Solit DB; Scher HI; Rosen N
Semin Oncol; 2003 Oct; 30(5):709-16. PubMed ID: 14571418
[TBL] [Abstract][Full Text] [Related]
9. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.
Jang YG; Go RE; Hwang KA; Choi KC
J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
12. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol.
Sharma SV; Agatsuma T; Nakano H
Oncogene; 1998 May; 16(20):2639-45. PubMed ID: 9632140
[TBL] [Abstract][Full Text] [Related]
13. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
[TBL] [Abstract][Full Text] [Related]
14. Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP.
Mizokami A; Saiga H; Matsui T; Mita T; Sugita A
Endocrinol Jpn; 1992 Jun; 39(3):235-43. PubMed ID: 1425449
[TBL] [Abstract][Full Text] [Related]
15. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
16. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells.
Hsu FN; Yang MS; Lin E; Tseng CF; Lin H
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E902-8. PubMed ID: 21364123
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor.
Dagar M; Singh JP; Dagar G; Tyagi RK; Bagchi G
J Biol Chem; 2019 May; 294(22):8699-8710. PubMed ID: 30992362
[TBL] [Abstract][Full Text] [Related]
19. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
20. Development of radicicol analogues.
Soga S; Shiotsu Y; Akinaga S; Sharma SV
Curr Cancer Drug Targets; 2003 Oct; 3(5):359-69. PubMed ID: 14529387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
